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ABSTRACT

Here we disclose the response of normal human cells to ZnO
nanoparticles under different signaling environments and
compare it to the response of cancerous cells. ZnO nanoparticles exhibit a strong preferential ability to kill cancerous T
cells (-28-35X) compared to normal cells. Interestingly, the
activation state of the cell contributes toward nanoparticle
toxicity as resting T cells display a relative resistance while
cells stimulated through the T cell receptor and CD28
costimulatory pathway show greater toxicity in direct relation
to the level of activation. The novel findings of cell selective
toxicity towards potential disease causing cells indicate a
potential utility of ZnO nanoparticle in the treatment of cancer and/or autoimmunity.
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Effect of ROS inhibition on viability
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PREFERENTIAL KILLING OF CANCER
CELLS AND ACTIVATED HUMAN T CELLS
USING ZNO NANOPARTICLES

213903). The aim of the study was to investigate whether ZnO
NP induce toxicity in a cell-specific manner, determine the
mechanism( s) of toxicity, and whether these NPs have potential utility in novel biomedical applications seeking to eliminate pathogenic cells while sparing healthy body tissues.

This application claims priority of Provisional Application
Ser. No. 601974,460, filed Sep. 22, 2007, and entitled "Preferential Killing of Cancer Cells and Activated Human T Cells
Using the Selective Toxicity of Zinc Oxide," which is hereby
incorporated by reference.
This research was supported in part by Mountain States
Tumor and Medical Research Institute, Boise, Id., NSFIdaho-EPSCoR Program (EPS-0447689), DoE-EPSCoR
grant (DE-FG02-04ER46142), NSF grants (DMR-0449639,
MRI 0521315), and NIH (lR15 AI06277-0IAI). We thank
Dr. lames Belthofffor his gracious assistance with statistical
analysis.
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SUMMARY OF INVENTION
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BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to a new method for preferentially killing cancer and activated T cells with zinc oxide
(ZnO) nanoparticles. More specifically, this invention relates
to autoimmune disease and cancer treatment in humans and
animals by preferentially killing cancer and activated T cells
with relatively little damage to normal cells.
2. Background Art
The integration of nanotecluology and biology provides
the opportunity for the development of new materials in the
nanometer size range that may be applied to many potential
applications in biological science and clinical medicine.
When reduced to the nanoscale realm, unique size-dependent
properties of nanomaterials, including nanopaiticles (NP),
are manifested. The principal factors believed to cause properties of nanomaterials to differ from their bulk counterparts
include an increase in relative surface area and quantum
effects, which can affect chemical reactivity and other physical and chemical properties. For example, a particle oBO um
size has 5% of it atoms on its surface compared to 50% of the
atoms on the surface of a 3 nm particle. The altered properties
of NP, and their similarity in size compared to naturally
occurring biological structures, can allow them to readily
interact with biomolecules on both the cell surface and within
the cell and potentially affect cellular responses in a dynamic
and selective manner. Materials that exploit these characteristics are becoming increasingly attractive for use in novel
biomedical applications.
Although our understanding of the functioning of the
human body at the molecular and nanometer scale has
improved tremendously, advances in therapeutic options for
treating severe and debilitating diseases such as cancer and
autoimmunity have lagged by comparison. In this regard,
nanomedicine, which is the application of nanotechnology to
medical problems, can offer new approaches. With regards to
cancer treatment, most current anticancer regimes do not
effectively differentiate between cancerous and normal cells.
This indiscriminate action frequently leads to systemic toxicity and debilitating adverse effects in normal body tissues
including bone marrow suppression, neurotoxicity, and cardiomyopathy. Nanotechnology and nanomedicine can offer a
more targeted approach which promises significant improvements in the treatment of cancer. In this study we have
employed 8 nm zinc oxide (ZnO) NP in which the synthesis
and properties have been previously described (Reddy K M,
Feris K, Bell l, Wingett D G, Hanley C, Punnoose A 2007
Selective toxicity of zinc oxide nanoparticles to prokaryotic
and eukalyotic systems Applied Physics Letters 90 213902-
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Nanoparticles are increasingly being recognized for their
potential utility in biological applications including nanomedicine. Here we examine the response of normal human
cells to ZnO nanoparticles under different signaling environments and compare it to the response of cancerous cells. ZnO
nanoparticles exhibit a strong preferential ability to kill cancerous T cells (-28-35X) compared to normal cells. Interestingly, the activation state of the cell contributes toward nanoparticle toxicity as resting T cells display a relative resistance
while cells stimulated through the T cell receptor and CD28
costimulatory pathway show greater toxicity in direct relation
to the level of activation. Mechanisms of toxicity appear to
involve the generation of reactive oxygen species (ROS) with
cancerous T cells producing higher inducible levels than normal T cells. In addition, nanoparticles were found to induce
apoptosis and the inhibition of ROS was found to be protective against nanoparticle induced cell death. The novel findings of cell selective toxicity towards potential disease causing cells indicate a potential utility of ZnO nanoparticle in the
treatment of cancer and/or autoimmunity.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is two charts about ZnO NP toxicity on unactivated
verses activated primary human CD4+ T cells.
FIG. 2 is three charts about the activation of T cells promoting NP association.
FIG. 3 is two charts about differential cytotoxic effects of
ZnO NP on cancerous T cell lines and primary T cells.
FIG. 4 is a chart about viability effects of ZnO NP on
co-cultures of cancerous and normal T cells.
FIG. 5 is a chart about kinetics of ZnO NP toxicity on
immortalized and primary human T cells.
FIG. 6 is three charts about cellular production of ROS
following ZnO NP exposure.
FIG. 7 is a chart about quenching ofROS protecting against
NP-mediated cytotoxicity.
FIG. 8 is seven copies of photos about ZnO NP inducing
apoptosis in lurkat T cells.
FIG. 9 is three copies of photos about detection of apoptotic morphological changes in lurkat T cells treated with
ZnONP.
DESCRIPTION OF THE PREFERRED
EMBODIMENTS
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Materials and Methods
I. Preparation and Characterization of Zinc Oxide Nanoparticles
ZnO nanoparticles were synthesized in diethylene glycol
(DEG) by forced hydrolysis of zinc acetate at 1600 C. as
previously described and size control achieved by optimizing
the hydrolysis ratio. The ZnO NPs were separated from DEG
via centrifugation (15,000 rpm), washed with ethanol several
times and dried to obtain a nanoscale powder sample. The
ZnO chemical phase, crystallite size (8-13 nm) and shape
were confirmed using x-ray diffraction (XRD), transmission
electron microscopy (TEM) and spectrophotometry. The
nanoparticles were then reconstituted in phosphate buffered

US 8,187,638 B2
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saline (PBS) solution. After reconstitution, NPs were sonicated for 10 min and immediately vortexed before addition to
cell cultures.
In order to aid in the investigations, additional FITC encapsulated ZnO (FITC-ZnO) particles were synthesized by
forced hydrolysis and condensation of FITC-binding silane
and silicate to obtain the FITC-Si0 2 core (Burns A, Ow H,
and Wiesner U 2006 Fluorescent core-shell silica nanoparticles: towards "Lab on a Particle" architectures for nanobiotechnology. Chern. Soc Rev. 35 1028-1042) and then the ZnO
surface layer fonned using zinc salt as described previously
Wang H, Wingett D, Engelhard M H, Feris K, Reddy K M,
Turner P et al 2008 Fluorescent dye encapsulated ZnO particles with cell-specific toxicity for cancer treatment and biomedical applications submitted to J Material Science: Materials in Medicine. The core-shell structure of the -200 nm
sized FITC-ZnO particles and the presence of a surface layer
of 8-13 nm sized ZnO nanopaiticles were confinned using
TEM, XRD and x-ray photoelectron spectroscopy (XPS)
studies, and fluorescence properties were investigated using
photolnminescence spectroscopy and flow cytometry, as
reported previously.
2. Isolation ofCD4+ T Lymphocytes and Cell Culture
Written, informed consent was obtained from all blood
donors and the University Institutional Review Board
approved the study. Peripheral blood mononuclear cells
(PBMC) were obtained by Ficoll-Hypaque (Histopaque1077, Sigma, St. Louis, Mo.) gradient centrifugation using
heparinized phlebotomy samples. Cells were washed 3 times
with Hank's buffer (Sigma) and incubated at Ixl0 6 cells/mL
in RPMI-1640 (Sigma) containing 10% fetal bovine serum
(FBS). CD4+ cells were obtained by negative immunonmagnetic selection per manufacturer's instructions using a cocktail of antibodies against CD45RO, CD8, CDI9, CDI4,
CDI6, CD56, CD8, and glycophorinA (StemCell Technologies, Vancouver, B.C.) with collection of unlabeled T cells
(typically >96% CD4+ and >90% viable as assessed by flow
cytometry). Purified CD4+ cells were cultured in RPMI/lO%
FBS at Ix10 6 cells/ml in 200 flL total volume in 96-well
microtiter plates. The lurkat and Hut-78 T cell lines (ATTC,
Rockville, Md.) were cultured in RPMI 1640 supplemented
with 10% FBS (Jurkat) or 20% FBS (Hut-78) and 2 mM
L-glutamine, 1.5 giL sodinm bicarbonate, 4.5 giL glucose, 10
mM HEPES, and 1.0 mM sodinm pyruvate. Cells were maintained in log phase at 37° C. and 5% CO 2 and seeded at Ix10 5
cells/well in 96-well plates for individual experiments. To
prevent overgrowth in co-culture experiments, lurkat cells
were seeded at 5x104 cells/well and primary T cells were
seeded at Ix10 5 cells into the same well.
3. T-Cell Activation
For indicated experiments, primary human T cells were
activated using immobilized CD3 antibody (1.0 flglwell of
clone OKT3, ATCC, Rockville, Md.) +/-CD28 antibody
(0.25 flglwell of clone CD28.2, PharMingen, San Diego,
Calif.) in 96-well tissue culture plates. Cultures were treated
with freshly prepared and sonicated NP for varying lengths of
time and flow cytometry used to assess T cell viability via
staining with propidium iodide (PI: BD Biosciences). T cell
activation was verified by detecting an increase in membrane
CD40L protein expression using flow cytometry.
4. Cell Viability and Flow Cylometry Staining
Methods of immunofluorescent staining and flow cytometry were perfonned as previously described. Briefly, cells
were stained with fluorescently labeled antibodies (Beckman
Coulter, Miami, Fla.) for 30 minutes at 4° c., washed two
times, and immediately analyzed on a 3-color Epics flow
cytometer (Beckman Coulter). Five to ten thousand events

gated on size (forward scatter-FS) and granularity (side scatter-SSC) were analyzed, and expression of the percentage of
positively staining cells or the mean fluorescence intensity
(MFI) was determined by comparisons to isotype controls.
Appropriate concentrations of each antibody were determined by titration for optimal staining prior to experimental
use.
To assess cell viability, two different assays were
employed. In the first assay, T cells were dually stained with
fluoroscein isothiocyanate labeled antibodies (anti -CD4 for
primary T cells and anti-HLA ABC for T cancer cell lines)
followed by treatment with 50 flg/mL propidinm iodide (PI)
to monitor losses in membrane integrity. After 10 min of PI
staining, fluorescent CountBright counting beads (Invitrogen, Carlsbad, Calif.) were added to samples to enable determinations of absolute cell nnmbers, and changes in PI staining used to quantifY cell death. Nanoparticles were excluded
from analysis based on absence of fluorescence signal and
light forward scatter (FS) and side scatter (SSC) characteristics. A second viability assay, the LIVEIDEAD viability
assay for mammalian cells (Invitrogen, Eugene, Oreg.) was
used to verifY results. Per manufacturer's protocol for flow
cytometry, cells were dually stained with two fluorescently
labeled probes that enable the simultaneous detennination of
live and dead cells in a sample. CalceinAM was used to stain
live cells as it fluoresces only when cleaved by intracellular
esterases and EthD-I was used to identifY dead!dying cells as
it exclusively enters cells with disrupted cell membranes.
In co-culture experiments, lurkat cells and primary T cells
were distinguished from each other using differential gating
based on their differing and non-overlapping light scattering
properties indicative of size (FS) and granularity (SSC)
between the two cell types. FS and SSC of lurkat cells was
-2.2 and 3.2 times greater than for primary T cells, respectively.
5. ROS Production
To assay for reactive oxygen species (ROS) production,
primary hnman T cells were treated with the oxidation-sensitive dye, 2', 7'-dichlorofluorescein diacetate (DCFH-DA;
Invitrogen, Carlsbad, Calif.). The oxidation product of
DCFH-DA has an excitation/emission maxima of -495
nml529 nm enabling detection using standard flow cytometry. Whole blood was treated with an ammonium chloride
solution (1.5 M NH4 CI, 0.1 M NaHC0 3 , 0.01 M EDTA) to
lyse red blood cells and centrifuged for 10 min at 4°C. to
remove erythrocytic debris. The white blood cells were then
resuspended in phenol red-free RPMI a Ix10 6 cells/mL and
treated with 13 nm ZnO NP.After 18 h of treatment, cultures
were loaded with 5 flM of DCFH-DA for 20 min and ROS
production evaluated using flow cytometry as previously
described. To ensure cells were capable of ROS production,
control samples were activated with 25 nglmL ofPMA for I
h after loading with DCFH -DA. White blood cell populations
(i.e. T lymphocytes andmonocytes) were distinguished by FS
and SSC characteristics and staining with fluorescently-Iabeled antibodies (e.g. CD3, CD 14). ROS production was also
perfonned in Hut-78 cells using similar methodology.
6. ROS Quenching
To detennine the role of ROS in NP-induced cell death,
lurkat leukemia cells were seeded in a 96-well plate at 0.2 mL
per well at a concentration of 5xl 05 cells/mL. A stock solution ofN-Acetyl Cysteine (NAC, Sigma Aldrich) was made in
sterile nanopure water and added to cells at 5 mM or 10 mM
for I h. After NAC pretreatment, cells were cultured with
0.3-0.5 mM ZnO NP for 24 h. Viability was determined by PI
exclusion and flow cytometry with fluorescent CountBright

5

10

15

20

25

30

35

40

45

50

55

60

65

US 8,187,638 B2

5

6

counting beads (Invitrogen, Carlsbad, Calif.) added to
samples to enable detennination of absolute cell numbers.
7. Detection of Apoplosis
Mechanisms of ZnO NP induced cytotoxicity was evaluated by confocal microscopy using two different staining
techniques; acridine orange and Vybrant® Apoptosis Assay
Kit #2-AlexaFluor® annexin V/propidium iodide by Invitrogen (Eugene, Oreg.). Acridine orange stains double
stranded DNA and allows for visualization of nuclear morphology. Invitrogen's Vybrant annexin V assay makes use of
two different fluorescently labeled probes, annexin V and PI,
to differentiate between live, necrotic and apoptotic cells.
Briefly, lurkat T cells were suspended in complete RPMI1640 medium and plated at 5x1Os on poly-d lysine coated
glass bottom culture dishes (P35GC-1.5 mm-14 mm-C) supplied by MatTek Corporation (Ashland, Mass.). Samples
were left untreated, treated with 0.3 mM ZnO NP, or with 100
nM okadaic acid as a positive control for apoptosis. Following a 20 h incubation at 37° C. (5% CO 2 ), cells were washed
and stained with annexin V antibody/PI per manufacturer's
protocol or stained with 5 flglmL acridine orange for 10 min
at 37° c., followed by washing and resuspension in PBS.
Cells were visualized using a Zeiss LSM 510 META laser
scanning confocal microscope (Zeiss, Gennany). Images
were acquired using factory-set dichronics (an argon laser set
and two helium neon lasers) with either a 63x Plan Apochromat 1.4 oil DIC or 100x Plan Fluar 14.5 oil objective. Image
acquisition and processing was performed using the LSM 510
META software.
8. Statistical Analyses
All data was analyzed using SAS, Inc. software (Cary,
N.C.). Data for FIGS. 1, 3A, and 4 were analyzed using
repeated measures of valiance with post hoc comparisons and
significance levels defined as p<0.05. Repeated measures of
variance analyses were used when two or more measurements
of the same type were made on the same subject to detennine
statistical differences between the means and allow withinsubject variation to be separated from between-subject variation. Data for FIGS. 3B and 7 were analyzed using a two-way
analysis of variance (ANOVA) to test for statistical significance of the model and post hoc comparisons were used to
test for statistically significant effects of treatment on cell
viability (p<0.05).
Results
1. Activated T Cells are Preferentially Killed by ZnO NP
Previous studies from our laboratory have determined that
toxicity of ZnO NP occurs in a cell dependent manner. For
example, both gram negative and grain positive bacteria are
killed at substantially lower ZnO NP concentrations than
human T cells. To detennine if differential toxicity to ZnO NP
is dependent upon the microenvironment or signaling status
of cell, toxicity effects were determined in resting primary
human T cells and compared to cells activated through the T
cell receptor (TCR). Nonnal peripheral blood CD4+ T cells
were isolated using negative immunomagnetic selection and
either activated with stimulatory TCR antibodies (anti-CD3),
costimulated with anti-CD3/anti-CD28, or left unactivated.
The effects of ZnO NP on plasma membrane damage was
assessed using propidium iodide (PI), a red fluorescent
nuclear stain that enters only cells with disrupted plasma
membranes.
According to FIG. 1, ZnO NP toxicity on unactivated versus activated primary human CD4+ T cells. A) Human peripheral blood CD4+ T cells were isolated (purity >95%) and
activated with anti-CD3 antibodies, a combination of antiCD3 and anti-CD28, or left unactivated. Cultures were concurrently treated with varying concentrations of ZnO NP for

22-24 h and cell viability determined using flow cytometry
and PI uptake (means±standard error, n=6). Statistical analysis was performed using repeated measures analysis of variance and model based means post hoc test (p<0.05) with an
asterisk denoting statistical significance. B) Verification ofT
cell activation was detennined by concurrently monitoring
expression of membrane CD40L protein using flow cytometry (means±standard error, n=5). As shown in FIG. lA, the
toxicity of ZnO NP to T cells is dependent on the activation
state of the cell. Resting T cells displayed the most resistance
to ZnO NP, with an IC so of -5.9 mM. The inactivated status of
these cells was verified by their lack of appreciable CD40L
protein expression, a sensitive marker of T cell activation
(FIG. IB). Conversely, T cells partially activated by stimulation thorough the TCR pathway alone displayed significantly
greater sensitivity to ZnO NP at all concentrations tested
(p=0.0007 for control vs. CD3 at 1 mM, p=0.0009 at 5 mM
and p=0.0052 at 10 mM NP). The partial activation status of
these cells was verified by 38%±6.2% of the cells expressing
membrane CD40L. Importantly, T cells activated through
both the TCR and CD28 costimulatory pathway showed an
even greater sensitivity to ZnO NP toxicity (e.g. 55% viability
in CD3/CD28 activated vs. 69% in CD3 activated cells at 1
mM) which significantly differed from CD3 activated cultures at both 1 mM (p=0.0044) and 5 mM NP (p=0.0246)
concentrations. Staining for membrane CD40L expression
was used to confinn a greater extent of T cell activation in
CD3/CD28 activated cultures (67%± 7.0% cells staining positive for membrane CD40L). Control experiments using bulk
micron sized ZnO powder or NP-free supernatant showed no
appreciable toxicity effect at any of the concentrations tested
(viability with bulk ZnO: 95±0.5% at 0 mM, 96±3% at 1 mM,
91±3% at 5 mM, 91±1 % at 10 mM; 98% viability with
NP-free supernatant equivalent to 1-10 mM) consistent with
our previous observations.
In addition to PI uptake associated with disruption of membrane integrity, cell death following ZnO NP treatment was
also supported by an increase (-17%; MFI change of 48 to 56)
in light side scatter characteristics which is indicative of
increased cellular granularity and a concurrent decrease
(-8%; MFI change of 156 to 144) in forward scatter which
reflects a decrease in cellular size at 10 mM NP concentrations that induce -60% cell death. These results demonstrate
that significantly more cell death is observed in activated T
cells compared to resting cells over a relatively large range of
NP concentrations tested (1-10 mM), and toxicity varies with
the extent ofT cell activation.
2. ZnO NP Preferentially Associate with Activated T Cells
To gain insights into mechanisms of differential cell toxicity, experiments were perfonned to determine whether NP
preferentially associate with activated T cells compared to
resting T cells. FITC-encapsulated ZnO NP (FITC-ZnO-NP)
were prepared as described and their fluorescence properties
used to monitor cell uptake/association. Primary CD4+ T
cells were either left unactivated or activated with CD3/CD28
antibodies and treated with 5 mM FITC-ZnO-NP for 4 h.
Dual color flow cytometry was used to analyze changes in the
FITC-NP signal on gated CD4+ T cells.
According to FIG. 2, the activation ofT cells promotes NP
association. Primary CD4+ T cells (>96% purity) were left
untreated or activated with immobilized CD3/CD28 antibodies and cultures concurrently treated with 5 mM FITC encapsulated ZnO NP for 4 h. Cells were stained using an ECDlabeled CD4 Ab. Using flow cytometry, 10,000 events gated
on CD4+ cells were analyzed for changes in FITC fluorescence. Data from a representative histogram is presented with
panel A) showing resting T cells cultured with FITC encap-
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sulated NP and panel B) showing activated T cells cultured
with FITC encapsulated NP. Inset numbers depict the percentage ofFITC positive cells. The positioning of the quadrant on the x-axis was determined using T cells cultured
without fluorescently labeled NP and set so I % of cells
appeared in quadrant 2. C) depicts a dose-dependent increase
in NP association with T cells, n=3 with error bars depicting
standard error. As shown in FIG. 2, resting T cells had a low
NP associated fluorescence signal (12.5% FITC positive)
while a substantially greater FITC signal (48.4% positive)
was observed for activated T cells. A dose-dependent uptake
ofFITC-ZnO-NP was noted with greater NP association at 5
mM compared to I mM concentrations (-3.3 greater attachment at 5 mM; FIG. 2C). At the early time points evaluated in
these studies, NP labeling did not appear to reflect a generalized increase in membrane permeability as no PI uptake
indicative of cytotoxicity was observed following 4 h of exposure with 5 mM FITC-ZnO-NP. However, the expected loss of
cell viability (73%±7.3% sue., n=3 with 1.25 mM) was
detected upon extended 24 h exposure indicating that FITCZnO-NP behave similarly to unlabeled ZnO NP. In addition,
our recent confocal microscopic studies have demonstrated
FITC-ZnO-NP uptake and intracellular localization by
human T cells. Collectively, these results indicate that the
cellular processes accompanying T cell activation (eg.
increased membrane protein expression, cell cycle progression) result in changes that promote strong physical interactions and consequent intracellular uptake of NP.
3. Preferential Killing of Cancerous Cells by ZnO NP
Given that differential ZnO NP toxicity exists between
quiescent T cells and those activated with specific signals to
trigger proliferation (FIG. 1), experiments were performed to
determine whether continuously dividing cancer cells display
an even greater sensitivity to ZnO NP toxicity. lurkat leukemic and Hut-78 lymphoma T cell lines were treated with ZnO
NP for 24 h and viability was determined by PI uptake. Both
T cell cancer lines displayed strikingly greater (28-35 fold)
sensitivity to NP toxicity compared to resting normal T cells
(FIG. 3).
According to FIG. 3, differential cytotoxic effects of ZnO
NP on cancerous T cell lines and primary T cells. A) lurkat,
Hut-78 T cell lines, or normal primary T cells were treated
with varying concentrations ofZnO nanopaiticles for 22-24 h
and viability determined by monitoring PI uptake using flow
cytometry as described for FIG. 1. Data from seven (lurkat),
three (Hut-78), and four (normal CD4+ T cells) independent
experiments is presented and error bars depict standard error.
Data was analyzed using a repeated measures ANOVA and
model based means post test. Statistical comparisons were
made between each cancer cell line and primary T cells at 0.1
mM and 0.5 mM ZnO NP with significance levels defined as
p<0.05 and indicated by an asterisk. B) lurkat and primary T
cell viability was assessed using the LIVEIDEAD®Viability/
Cytotoxicity Kit for mammalian cells (Invitrogen, Eugene,
Oreg.). Following ZnO NP exposure for 24 h, cells were
stained with calcein AM (green fluorescence) and ethidium
homodimer-I (red fluorescence) to differentiate between live
and dead cells, respectively. Data from a representative
experiment is presented with error bars depicting standard
error, n=3. A two-way analysis of variance combined with a
model based means test indicates significant differences in
viability between lurkat and primary T cells for all NP concentrations tested (asterisk denotes p<O.OOOI). Significant
differences were observed between Hut-78 and normal T
cells (p=0.010l and 0.0434 at I mM and 5 mM NP, respectively) and lurkat and normal T cells «0.0001 at both I mM
and 5 mM NP). An IC so of -0.17 mM was observed for

Hut-78 cells and -0.21 mM for lurkat T cells. No appreciable
loss of primary T cell viability was observed at NP concentrations (e.g. 0.5 mM) that effectively killed the cancerous T
cells.
To validate experimental results, a second viability assay
was employed. Similar experiments were performed using
the LIVE/DEAD viability assay (Invitrogen, Eugene, Oreg.)
which allows for the simultaneous determination of live and
dead cells in a sample by labeling live cells with the Calcein
AM dye that fluoresces only when cleaved by intracellular
esterase enzymes and the vital dye, EthD-I, which only enters
dead/dying cells with disrupted cell membranes. As shown in
FIG. 3B, nearly identical results were obtained using this
independent assay for viability, with ZnO NP displaying preferential toxicity against cancerous cells compared to normal
cells of identical lineage. It should be noted that no statistically significant change in primary T cell viability occurs
between untreated control cells and cells treated with low NP
concentrations (0.2 and 0.5 mM), while a significant decrease
(p<0.000l) in lurkat leukemia cell viability can readily be
seen at the lowest concentration tested (-52% viable/48%
dead at 0.2 mM) with no live cancer cells detectable at 5 mM
NP.
To verifY that preferential cancer cell killing occurs in the
direct presence of normal healthy T cells, co-culture experiments were performed. For these experiments, lurkat T cells
were co-cultured with primary CD4+ T cells, treated with
various concentrations of ZnO NP for 24 h, and cell viability
assessed by PI uptake.
According to FIG. 4, viability effects of ZnO NP on cocultures of cancerous and normal T cells. Individual wells in
a 96-well plate were seeded with lurkat and primary T cells
and treated with various concentrations of ZnO nanopaiticles
for 22-24 h. Viability was determined by monitoring PI
uptake using flow cytometry. Data from three independent
experiments is presented and error bars depict standard error.
Statistical analysis was performed using a repeated measures
ANOVA and model based means post hoc test. Significance
levels were defined as p<0.05 and are indicated by an asterisk.
FIG. 4 confirms the preferentially killing of cancerous lurkat
T cells with a very similar IC so value being observed for
co-cultured lurkat cells (IC so -0.28 mM) compared to these
cells cultured alone (FIG. 3). Again, only very limited cytotoxicity was observed on co-cultured normal T cells at corresponding NP concentrations with significant differences
(p<0.000l) between cell types being observed at 0.3,0.4, and
0.5 mM NP concentrations.
4. Kinetics of ZnO NP Mediated Toxicity
Additional experiments were performed to determine the
kinetics of ZnO NP toxicity in both primary and cancerous T
cells. Because primary and immortalized T cells have markedly different sensitivities to ZnO NP, concentrations were
chosen for each cell type (10 mM for primary T cells and 0.5
mM for lurkat T cells) that produce at least 75% cytotoxicity
by 24 h exposure.
According to FIG. 5, kinetics of ZnO NP toxicity on
immortalized and primary human T cells. Freshly isolated
CD4+ T cells (purity >96%) were treated with 10 mM ZnO
NP and lurkat T cells were treated with 0.5 mM ZnO NP for
varying times and viability determined using PI uptake and
flow cytometry. Means±standard error from representative
experiments are presented (n=3). As shown in FIG. 5, both
primary T cells and lurkat cells displayed similar kinetics
with appreciable lose of cell viability beginning as early as 8
h post treatment and full toxicity effects requiring a longer
treatment period of 24 h.
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5. ZnO NP Induce ROS Production
Several types of nanomaterials including quantum dots and
metal oxide NP have been shown to induce the generation of
excess reactive oxygen species (ROS) resulting in modification and damage of cellular proteins, DNA, and lipids which
can lead to cell death. To investigate oxidative stress produced
by ZnO NP as a mechanism of cellular toxicity, experiments
were performed using the cell permeable dye, DCFH -DA. In
the presence of reactive oxygen species, including hydrogen
peroxide and superoxide anion, DCFH-DA is oxidatively
modified into a highly fluorescent derivative that is readily
detectable using flow cytometry.
According to FIG. 6, cellular production ofROS following
ZnO NP exposure. ROS generation was evaluated in primary
T cells and monocytes and in the transformed Hut-78 T cell
line following 18-24 h of ZnO NP exposure using the oxidation sensitive dye DCFH-DA and flow cytometry. A & C)
Representative histograms depicting ROS production in primary T cells and monocytes. Assays were performed using
freshly obtained whole blood in which red blood cells were
removed following NH4 Cllysis. T lymphocytes and monocytes were gated based on staining with f1uorescently labeled
CD3 and CD14 antibodies and the oxidation product of
DCFH-DA detected using the FLI detector. B) Histogram
depicting ROS production in the transformed Hut-78 T cell
line. In each histogram, the light grey line depicts background
fluorescence in DCFH-DA loaded cells while the black line
depicts fluorescence in DCFH-DA loaded cells treated with
ZnO NP for 18 h (A & C) or 24 h (B). To assess relative
increases in ROS following NP treatment, a marker (M!) was
set so that background fluorescent in control samples (DCFH DA loaded/no NP) was between 1 and 3.5% and numbers in
parentheses indicate the percentage of fluorescence positive
cells. As shown in FIG. 6, a modest increase in DCF f1uorescence was observed after 18 h of 5 mM ZnO NP exposure in
primary lymphocytes (-7.0 fold increase-12.5/1.78) and an
even stronger induction observed in Hut-78 T leukemic cells
at 24 h (-14.0 fold increase). In addition, peripheral blood
monocytes produced robust levels (-25.1 fold increase) of
ROS following ZnO NP exposure consistent with the greater
capacity of these cells for ROS generation. Increased ROS
production was detectable as early at 8 h of NP exposure
although greater levels were apparent at 18-24 h (data not
shown). Because of the differing size and granularity properties of the cell types examined, different instrument voltage
parameters were required which prevents direct comparisons
of intrinsic levels of ROS between cell types.
6. Role of ROS in NP-Induced Cytotoxicity
Experiments were performed to determine if the T cell
death that results from NP exposure is dependent on the
generation of intracellular ROS. lurkat cells were exposed to
increasing concentrations of the antioxidant and ROS
quencher, NAC (N-acetyl cysteine) prior to treatment with
NP for 24 h.
According to FIG. 7, quenching of ROS protects against
NP-mediated cytotoxicity. lurkat cells were pretreated with
5-10 mM N-acetyl cysteine for 60 min and then treated with
0.3-0.5 mM ZnO NP.After 24 h, cell viability was determined
using propidium iodide exclusion and flow cytometry. Data
from a representative experiment performed in triplicate is
presented with error bars depicting standard error. A two way
analysis of variance was performed followed by a model
based means test to show significant differences in means of
cell viability (%) between treatments (asterisk denotes
p<O.OOOI). FIG. 7 shows that NAC has significant effects to
prevent NP-induced cytotoxicity with rescue being observed
at both NP concentrations tested. Significant differences

(p<0.000l) were observed between cultures not pretreated
with NAC and both NAC pretreatments (5 mM and 10 mM)
for each NP concentration tested. For example, with 10 mM
NAC, nearly 100% viability was retained even at an NP
concentration previously shown to reduce cell viability below
10%. These results indicate that ROS generation plays a
causal role in NP-induced cytotoxicity.
7. ZnO NP Induce Apoptosis
Experiments were performed to determine whether ZnO
NP induce apoptosis or necrosis in T cells. lurkat cells were
treated with 0.3 mMNP for 20 hand apoptosis observed using
two different experimental approaches. In the first assay, cells
were stained with a green fluorescent annexin V antibody
which reacts against externalized phosphatidylserine, a characteristic of apoptotic cells, and the red fluorescent propidium
iodide dye which stains both late-stage apoptotic and necrotic
cells displaying permeable membranes. As expected, viable
control cells show only very weak staining with annexin V
antibody and no detectable staining with PI (FIG. 8).
According to FIG. 8, ZnO NP induce apoptosis in lurkat T
cells. Cells were left untreated, treated with 0.3 mM ZnO NP
for 20 h, or treated with 100 nM okadaic acid for 20 h (positive
control) and stained with a green fluorescent annexin V antibody to detect apoptotic membranes and the red fluorescent
dye PI to detect permeable membranes using the Vybrant
apoptosis assay kit #2 (Molecular Probes). Cells were visualized by confocal microscopy and representative images are
shown. A-C) control cells not treated with NP; A) control
differential interference contrast (DICCimage, B) control DIC
image with green and red fluorescence overlay, C) control
green and red fluorescence image. D-G) cells treated with NP;
D) NP treated DIC image, E) NP treated DIC image with
green and red fluorescence overly, F) NP treated green and red
fluorescence image. G) an additional green and red fluorescence image ofNP treated cells oflower magnification. Conversely, cells treated with ZnO NP stain positive with the
apoptotic marker (eg. two out of the four cells in panel F and
four out of five cells in panel G show green fluorescence
only). Some dually stained were also observed as expected
for late-stage apoptotic cells with permeable membranes. To
further verify NP-induced apoptosis, similar cell cultures
were stained with the DNA dye, acridine orange, which is
used to detect apoptotic morphology characterized by nuclear
fragmentation, cellular shrinkage, and chromatin condensation.
According to FIG. 9, detection of apoptotic morphological
changes in lurkat cells treated with ZnO NP. Cells were left
untreated (A), or treated with 100 nM okadaic acid for 20 h as
a positive control for apoptosis (B), or treated with 0.3 mM
ZnO NP for 20 h (C) and stained with acridine orange and
visualized by fluorescent microscopy. Arrows indicate typical
apoptotic cells characterized by a shrunken appearance and
condensed or fragmented nuclei. As shown in FIG. 9, these
morphological changes were observed in NP treated cultures
and cells treated with the apoptosis inducer okadaic acid, but
not in control samples. Collectively, these results indicate that
ZnO NP induce apoptosis in lurkat T cells.
Discussion
In this study we examined the toxicity profiles of human
primary cells and transformed tumor cells to ZnO NP.
Because cellular response is dynamic and the ultimate phenotype is affected by a myriad of competing or overlapping
signals present in the microenvironment, studies were performed to determine how ZnO NP affect quiescent cells compared to rapidly dividing tumor cells and whether different
activation stimuli result in different toxicity responses. Here
we present novel findings demonstrating that cancerous T
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cells are markedly more susceptible (-28-35 times) to ZnO
NP mediated toxicity than their normal counterparts (FIG. 3).
These findings may be of important clinical interest as one of
the greatest challenges facing chemotherapy is the inability of
anticancer drugs to effectively distinguish between normal
and transformed tissue. Although many commonly used chemotherapeutic drugs target rapidly dividing cells, many suffer
from a relatively low therapeutic index, that is, the ratio of
toxic dose to effective dose. This limitation frequently causes
a broad range of toxicities leading to dose limiting toxicity
and a concomitant reduction in antitumor efficacy. Importantly, the preferential toxicity of ZnO NP towards cancerous
T cells is of substantial magnitude, especially in comparison
to ex vivo indices reported for other commonly used chemotherapeutic agents using similar cell viability assays. Therapeutic indices of ~ 10 have been reported for both doxorubicin and carboplatin against a variety of tumors including
acute myelogenous leukemia, non-Hodgkin's lymphoma,
ovarian, and other solid tumors. Thus, the inherent differential toxicity of ZnO NP against rapidly dividing cancer cells
raises exciting opportunities for their potential use as anticancer agents, and the selectivity of these nanomaterials can be
expected to be even further enhanced by design by linking
tumor targeting ligands such as monoclonal antibodies, peptides, and small molecules to tumor-associated proteins, or by
using NP for drug delivery.
The preferential killing of rapidly dividing cancer cells
relative to quiescent cells of the same lineage suggests that
mechanisms of ZnO NP toxicity might be related to the proliferative potential of the cell. This hypothesis is further supported by studies comparing responses in healthy primary
resting T cells to identical cultures in which cells were either
activated thorough the T cell receptor signaling pathway or
via both TCR and CD28 co stimulation pathways (FIG. 1).
Signal transduction through the TCR pathway is recognized
as an essential event required for resting T cells to enter the
cell cycle and proliferate. A second signal provided by ligation through the CD28 receptor protein augments TCR signaling and enables maximal T cell activation and proliferation. Thus, our findings revealing a spectrum of toxicity
profiles that correlate with the activation status and proliferative capacity of the cell supports the hypothesis that ZnO NP
preferentially target rapidly dividing cells. Quiescent T cells
displayed the most resistance to ZnO NP while TCR stimulated cells had less resistance. Importantly, TCRlCD28
costimulated T cells were the most sensitive to ZnO NP
toxicity and a greater cell association with fluorescently
labeled ZnO NP was observed in activated T cells compared
to quiescent T cells (FIG. 1). These findings indicate that the
selective elimination of activated T cells may be feasible,
when desired, such as in the treatment of auto immunity.
In a number of autoimmune diseases including multiple
sclerosis and psoriasis, self-reactive T cells are a pathogenic
subset underlying disease processes and exist in a predominately activated state as they are continually exposed to specific antigen present in normal body tissue. Because only a
very small percentage of the total T cell repertoire are selfreactive and pathogenic in autoimmunity, the ability of identical concentrations of ZnO NP to preferentially induce cytotoxicity in self-reactive activated T cells while leaving the
unactivated T cell repertoire largely intact and immunity
uncompromised against future infections is an incredibly
attractive approach which may ultimately become feasible.
Based on data presented here, ZnO NP hold promise in this
novel biomedical application, especially if their selectivity
against self-reactive pathogenic cells can be improved by the

covalent attachment of antibodies specific to proteins
expressed predominantly on activated T cells such as CD40L
andOX40.
A number of studies indicate that certain nanomaterials,
including metal oxide NP, have the potential to exhibit spontaneous ROS production based on material composition and
surface characteristics while other nanomaterials trigger ROS
production only in the presence of select cell systems. Results
from our flow cytometry experiments provide the first evidence of ROS production in a biotic enviroument following
ZnO NP exposure. These findings have important implications regarding mechanisms of cellular toxicity as elevated
ROS production that exceeds the capacity of the cellular
antioxidant defense system causes cells to enter a state of
oxidative stress which results in damage of cellular components such as lipids, proteins, and DNA. The oxidation of
fatty acids then leads to the generation oflipid peroxides that
initiate a chain reaction leading to disruption of plasma and
organelle membranes and subsequent cell death. We observed
a concentration and time dependent increase in ROS production in primary T cells following ZnO NP exposure (FIG. 6),
with even higher levels being observed in monocytes consistent with the ability of these cells to generate large amounts of
ROS during an immune response. Interestingly, immortalized
T cells produced greater levels of ROS than primary T cells
which may mechanistically underlie the greater susceptibility
of cancerous T cells to NP-mediated toxicity. Indeed, studies
using the ROS quencher, NAC, demonstrated the causal role
ofROS generation in NP-mediated cytotoxicity (FIG. 7).
As there is increasing evidence that elevated ROS acts as a
critical signaling molecule in the induction of apoptosis
induced by many different stimuli, studies were performed to
determine ifNP induced cytotoxicity occurs via an apoptotic
pathway. Results presented in FIGS. 8 and 9 provide strong
evidence that ZnO NP induce apoptosis in cells ofT lymphocyte lineage. Collectively, these studies indicate that a primary mechanism of ZnO NP cytotoxicity may precede by
inducing the generation of ROS which then underlies the
induction of apoptosis, a process that may be prevented by
antioxidants and ROS quenchers. These observations may
provide the basis for the development of new rational strategies to protect against NP toxicity or enhance the destruction
of disease causing cell types such as cancer cells.
Conclusion
The key findings of this work support the view that ZnO NP
induce toxicity in a cell-specific and proliferation dependent
mauner with rapidly dividing cells being the most susceptible
and quiescent cells being the least sensitive. The marked
difference in cytotoxic response between cancer cells and
their normal counterparts, as well as differences between
activated and resting T lymphocytes, suggests an exciting
potential for ZnO NP as novel alternatives to cancer chemotherapy and radiation therapy as well as new approaches for
treatment of autoimmunity.
Although this invention has been described above with
reference to particular means, materials and embodiments, it
is to be understood that the invention is not limited to these
disclosed particulars, but extends instead to all equivalents
within the scope of the following claims.
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What we claim is:
1. A method of killing cancer cells, the method comprising:
providing a cancer cell in the presence of a healthy cell,
wherein the cancer cell is from leukemia and/or lymphoma;
contacting the cancer cell and the healthy cell with a ZnO
nanoparticle,
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wherein the ZnO nanoparticle has a preferential asso12. A method of treating auto immune disease, the method
ciation with the cancer cell over the healthy cell, and
comprising:
wherein a targeting ligand is not associated with the ZnO
providing an activated T-cell in the presence of a normal
nanoparticle; and
body tissue,
wherein the activated T-cell has become activated due to
killing the cancer cell.
2. The method of claim 1, wherein the ZnO nanoparticle is
multiple sclerosis or psoriasis;
at a concentration of about 0.1 mM to about 5 mM.
contacting the activated T-cell with a ZnO nanoparticle,
3. The method of claim 1, wherein the preferential assowherein the ZnO nanoparticle has a preferential association of the ZnO nanoparticle with the cancer cell comciation with the activated T-cell over the normal body
10
prises intracellular uptake of the ZnO nanoparticle.
tissue; and
4. The method of claim 1, wherein the ZnO nanoparticle
generating a reactive oxygen species within the activated
kills the cancer cell via an apoptotic pathway.
T-cell at a greater concentration than in the normal body
5. The method of claim 4, wherein the apoptotic pathway is
tissue.
induced by a reactive oxygen species produced because of the
13. The method of claim 12, wherein a targeting ligand is
15 not associated with the ZnO nanoparticle.
presence of the ZnO nanoparticle.
14. The method of claim 12, wherein the ZnO nanoparticle
6. The method of claim 1, wherein the ZnO nanoparticle
induces the generation of reactive oxygen species within the
is at a concentration of about 0.1 mM to about 5 mM.
cell.
15. The method of claim 12, wherein the preferential association of the ZnO nanoparticle with the activated T-cell com7. A method of preferentially inducing apoptosis in activated T-cells over resting T-cells, the method comprising:
20 prises intracellular uptake of the ZnO nanoparticle.
providing an activated T-cell in the presence of a resting
16. The method of claim 12, wherein the reactive oxygen
T-cell;
species induce apoptosis.
contacting the activated T-cell and the resting T-cell with a
17. A method of treating cells exposed to a ZnO nanoparZnO nanoparticle,
ticle, the method comprising:
wherein the ZnO nanoparticle has a preferential asso- 25
providing a cell exposed to a ZnO nanoparticle; and
ciation with the activated T-cell; and
contacting the cell with an antioxidant or a reactive oxygen
inducing apoptosis in the activated T-cell without exciting
species quencher.
18. The method of claim 17, wherein a targeting ligand is
the ZnO nanoparticle with electromagnetic radiation.
8. The method of claim 7, wherein a targeting ligand is not
not associated with the ZnO nanoparticle.
30
associated with the ZnO nanoparticle.
19. The method of claim 17, wherein a targeting ligand is
9. The method of claim 7, wherein the ZnO nanoparticle is
associated with the ZnO nanoparticle.
20. The method of claim 17, wherein the ZnO nanoparticle
at a concentration of about 0.1 mM to about 5 mM.
10. The method of claim 7, wherein the preferential assois internalized into the cell.
ciation of the ZnO nanoparticle with the activated T-cell com21. The method of claim 17, wherein the antioxidant or the
35 active oxygen species quencher prevents the induction of
prises intracellular uptake of the ZnO nanoparticle.
11. The method of claim 7, wherein apoptosis is induced by
apoptosis.
a reactive oxygen species produced in the presence of the
ZnO nanoparticle.
* * * * *

